Jung Won Shin
Senior Editor
Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.
Latest From Jung Won Shin
Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents
Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.
SK Biopharm Moves Into Radiopharma Via $572m Full-Life Deal
After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.
Q2 Korean Biotech Roundup: Partners Return Multiple Assets
The second quarter in South Korea was marked by the return of several assets by licensing partners, including Thea Open Innovation, which gave back rights to two ophthalmic programs in-licensed from OliX. Merck & Co. also cancelled a co-research deal with Artiva Biotherapeutics.
VC-Led Biotech Model Systemically Difficult To Adopt In Korea
A research fellow at South Korea's Science and Technology Policy Institute talked at a recent seminar about the key funding, management and other challenges faced by the domestic biotech sector to sustain growth, and how these contrast with the situation in the US.
Asia Deal Watch: ProGen To Partner With Rani On GLP-2 Agonist In Obesity
Plus deals involving Healios/Astellas Institute for Regenerative Medicine, Otsuka/Ionis, IMBiologics/Navigator and more.
SK Bioscience Snaps Up IDT Biologika To Accelerate Growth
SK Bioscience’s acquisition of top 10 CDMO marks first major acquisition as part of its growth acceleration strategy and the biggest such investment so far by a Korean vaccines firm. Execs say deal is aligned with SK Group’s wider moves to 'rebalance' its businesses.